Publications by authors named "Salima Hateb"
Article Synopsis
- The study focuses on SB5, an adalimumab biosimilar approved in Europe in 2017, and aims to gather real-world data on its usage and effectiveness in patients with various immune-mediated inflammatory diseases (IMIDs).
- Researchers analyzed clinical and healthcare claims data from the French national healthcare database to assess patient persistence on SB5 after 12 months.
- Among 911 patients treated with SB5, notable remission rates were observed at the 12-month mark, particularly in naïve patients, across various conditions such as rheumatoid arthritis and Crohn's disease, with all showing significant improvement from baseline.